GlassScriptPhysician profile
Andrzej Zeglen
NPI 1578092805
$2,639.56
in general payments reported to CMS, 2019-2025
24 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $315 · 2022: $511 · 2023: $566 · 2024: $788 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.11 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $422.92 | 2023-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $358.11 | 2021-2025 | |
| Abbvie INC. | $334.31 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $273.42 | 2021-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $244.37 | 2023-2025 | Fetroja |
| Astellas Pharma US INC | $177.24 | 2021-2025 | Cresemba |
| Viiv Healthcare Company | $142.86 | 2024-2025 | Cabenuva |
| Melinta Therapeutics, LLC | $123.90 | 2021-2023 | Vabomere, Orbactiv, Kimyrsa |
| La Jolla Pharmaceutical Company | $106.72 | 2024-2025 | Xerava, Zevtera |
| Amgen INC. | $76.19 | 2020-2024 | Tavneos |
| Janssen Pharmaceuticals, INC | $53.50 | 2020 | |
| Mylan Specialty L.P. | $40.44 | 2020 | |
| Calliditas Therapeutics US INC. | $39.67 | 2023-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $34.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $30.50 | 2023-2024 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $27.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.31 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $24.69 | 2025 | |
| Aimmune Therapeutics, INC. | $23.02 | 2023 | |
| Pfizer INC. | $20.41 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.73 | 2023 | Jynarque |
| Oxford Immunotec USA INC | $15.33 | 2022 | |
| Novo Nordisk INC | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrzej Zeglen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.